FIELD: biotechnologies.
SUBSTANCE: invention describes antisense compounds capable of reduction of level of factor 11 and methods for treatment or prevention of thromboembolic disorders with an individual who requires it. Examples of pathogenic compounds that can be subject to treatment by introduction of antisense compounds aimed at factor 11 are thrombosis, embolism and thrombembolia, such as deep venous thrombosis, pulmonary embolism, myocardial infraction and cerebral crisis. Antisense compounds aimed at factor 11 can be also used as prophylactic agents for elimination of a risk of development of thrombosis and embolism with individuals.
EFFECT: improving compound application efficiency.
57 cl, 169 tbl, 47 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATION OF FACTOR 11 EXPRESSION | 2014 |
|
RU2739594C2 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | 2015 |
|
RU2703411C2 |
| MODULATION OF HUNTINGTIN EXPRESSION | 2010 |
|
RU2562861C2 |
| ANTISENSE MODULATION OF GCGR EXPRESSION | 2012 |
|
RU2598709C2 |
| MODULATORS OF GROWTH HORMONE RECEPTOR | 2014 |
|
RU2700244C2 |
| METHODS AND COMPOSITIONS FOR MODELING EXPRESSION OF APOLIPOPROTEIN (A) | 2013 |
|
RU2624028C2 |
| COMPOSITIONS FOR MODULATING EXPRESSION OF SOD-1 | 2015 |
|
RU2704619C2 |
| COMPOSITIONS FOR MODULATION OF ATAXIN 2 EXPRESSION | 2015 |
|
RU2702838C2 |
| COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR EXPRESSION B | 2015 |
|
RU2701645C2 |
